| Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci FR Schumacher, AA Al Olama, SI Berndt, S Benlloch, M Ahmed, ... Nature genetics 50 (7), 928-936, 2018 | 827 | 2018 |
| Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the … RF Gabitass, NE Annels, DD Stocken, HA Pandha, GW Middleton Cancer Immunology, Immunotherapy 60, 1419-1430, 2011 | 691 | 2011 |
| A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer AA Al Olama, Z Kote-Jarai, SI Berndt, DV Conti, F Schumacher, Y Han, ... Nature genetics 46 (10), 1103-1109, 2014 | 532 | 2014 |
| Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade A Samson, KJ Scott, D Taggart, EJ West, E Wilson, GJ Nuovo, S Thomson, ... Science translational medicine 10 (422), eaam7577, 2018 | 377 | 2018 |
| Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction DV Conti, BF Darst, LC Moss, EJ Saunders, X Sheng, A Chou, ... Nature genetics 53 (1), 65-75, 2021 | 357 | 2021 |
| Measles virus causes immunogenic cell death in human melanoma OG Donnelly, F Errington-Mais, L Steele, E Hadac, V Jennings, K Scott, ... Gene therapy 20 (1), 7-15, 2013 | 216 | 2013 |
| Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients RA Adair, V Roulstone, KJ Scott, R Morgan, GJ Nuovo, M Fuller, D Beirne, ... Science translational medicine 4 (138), 138ra77-138ra77, 2012 | 209 | 2012 |
| Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus J Qiao, H Wang, T Kottke, C White, K Twigger, RM Diaz, J Thompson, ... Clinical Cancer Research 14 (1), 259-269, 2008 | 204 | 2008 |
| Genome-wide meta-analyses of breast, ovarian, and prostate cancer association studies identify multiple new susceptibility loci shared by at least two cancer types SP Kar, J Beesley, A Amin Al Olama, K Michailidou, J Tyrer, ZS Kote-Jarai, ... Cancer discovery 6 (9), 1052-1067, 2016 | 195 | 2016 |
| Combination therapy with reovirus and anti-PD-1 blockade controls tumor growth through innate and adaptive immune responses K Rajani, C Parrish, T Kottke, J Thompson, S Zaidi, L Ilett, KG Shim, ... Molecular Therapy 24 (1), 166-174, 2016 | 193 | 2016 |
| Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts TM Seibert, CC Fan, Y Wang, V Zuber, R Karunamuni, JK Parsons, ... bmj 360, 2018 | 186 | 2018 |
| Immunotherapeutic potential of whole tumour cells S Ward, D Casey, MC Labarthe, M Whelan, A Dalgleish, H Pandha, ... Cancer Immunology, Immunotherapy 51, 351-357, 2002 | 178 | 2002 |
| Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other … JB Bartlett, A Michael, IA Clarke, K Dredge, S Nicholson, H Kristeleit, ... British journal of cancer 90 (5), 955-961, 2004 | 169 | 2004 |
| Engrailed-2 (EN2): a tumor specific urinary biomarker for the early diagnosis of prostate cancer R Morgan, A Boxall, A Bhatt, M Bailey, R Hindley, S Langley, HC Whitaker, ... Clinical Cancer Research 17 (5), 1090-1098, 2011 | 166 | 2011 |
| The biology of the sodium iodide symporter and its potential for targeted gene delivery M Hingorani, C Spitzweg, G Vassaux, K Newbold, A Melcher, H Pandha, ... Current cancer drug targets 10 (2), 242-267, 2010 | 164 | 2010 |
| E‐cadherin expression in bladder cancer using formalin‐fixed, paraffin‐embedded tissues: correlation with histopathological grade, tumour stage and survival KN Syrigos, T Krausz, J Waxman, H Pandha, G Rowlinson‐Busza, ... International journal of cancer 64 (6), 367-370, 1995 | 154 | 1995 |
| Pretreatment frequency of circulating IL‐17+CD4+ T‐cells, but not Tregs, correlates with clinical response to whole‐cell vaccination in prostate cancer patients E Derhovanessian, V Adams, K Hähnel, A Groeger, H Pandha, S Ward, ... International journal of cancer 125 (6), 1372-1379, 2009 | 147 | 2009 |
| The role of autologous transplantation in patients with multiple myeloma aged 65 years and over B Sirohi, R Powles, J Treleaven, P Mainwaring, S Kulkarni, H Pandha, ... Bone marrow transplantation 25 (5), 533-539, 2000 | 147 | 2000 |
| Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables A Michael, G Ball, N Quatan, F Wushishi, N Russell, J Whelan, ... Clinical cancer research 11 (12), 4469-4478, 2005 | 145 | 2005 |
| Large-scale transcriptome-wide association study identifies new prostate cancer risk regions N Mancuso, S Gayther, A Gusev, W Zheng, KL Penney, Z Kote-Jarai, ... Nature communications 9 (1), 4079, 2018 | 144 | 2018 |
